FBIOP
Fortress Biotech, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Buy
+43/100
Last price
18.03
▼ 0.55 (2.96%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
17.50
Prev close
18.58
Day high
18.16
Day low
17.50
Volume
3.95K
Market cap
—
P/E (TTM)
—
52W range
6.27 – 21.43
Day trading desk
Gap from prior close
-5.81%
Prior close 18.58
VWAP
17.96
+0.38% from price
Relative volume
0.25×
Quiet session
Session range
3.76%
17.50 – 18.16
Position in range
80%
Near session high
ATR (14D)
0.68
3.77% of price
Prior day high
18.58
PDH
Prior day low
17.50
PDL
Bid / ask spread
—
Quote not published
Session volume
3.19K
Avg 12.68K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+9.20%
+7.3%
1M
-3.33%
-4.8%
3M
-4.10%
-7.5%
6M
+29.80%
+14.8%
YTD
+89.98%
+76.0%
1Y
+143.31%
+127.6%
3Y
+54.72%
-27.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on FBIOP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap—
Enterprise value$518.35M
Revenue (TTM)$68.47M
Gross profit$43.32M
EBITDA$-24.98M
Net income$103.37M
EPS (TTM)$-0.86
Free cash flow$-17.14M
Total cash$196.58M
Total debt$53.32M
Book value / share$4.93
Shares outstanding56.68M
Float21.44M
Short % of float—
Dividend yield0.00%
Beta (5Y)1.25
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book3.66
EV / revenue7.57
EV / EBITDA-20.75
Gross margin63.28%
Operating margin-53.46%
Profit margin163.32%
Return on equity115.98%
Return on assets-7.76%
Debt / equity25.87
Current ratio3.96
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $63.26M | $57.67M | $84.51M | $75.74M | +9.7% |
| Operating revenue | $61.24M | $56.67M | $64.99M | $73.07M | +8.1% |
| Cost of revenue | $20.92M | $20.88M | $22.89M | $30.77M | +0.2% |
| Gross profit | $42.34M | $36.80M | $61.62M | $44.97M | +15.1% |
| Research & development | $11.90M | $56.88M | $106.07M | $134.88M | -79.1% |
| Selling, general & admin | $96.40M | $87.73M | $90.98M | $113.66M | +9.9% |
| Total operating expense | $112.56M | $148.04M | $200.82M | $248.53M | -24.0% |
| Operating income | -$70.22M | -$111.24M | -$139.20M | -$203.56M | +36.9% |
| Net interest income | -$7.62M | -$10.84M | -$12.31M | -$12.24M | +29.7% |
| Pre-tax income | -$33.53M | -$120.54M | -$153.63M | -$213.46M | +72.2% |
| Tax provision | -$620.00K | $312.00K | $521.00K | $449.00K | -298.7% |
| Net income | $6.82M | -$46.00M | -$60.64M | -$86.58M | +114.8% |
| Net income to common | -$1.88M | -$55.89M | -$68.67M | -$94.61M | +96.6% |
| EBIT | -$24.83M | -$108.95M | -$141.72M | -$203.05M | +77.2% |
| EBITDA | -$20.16M | -$104.49M | -$135.72M | -$193.69M | +80.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.38M | $57.26M | $80.93M | $178.27M | — | +38.6% |
| Cash & short-term investments | $79.38M | $57.26M | $80.93M | $178.27M | — | +38.6% |
| Accounts receivable | $29.78M | $10.23M | $15.22M | $28.21M | — | +191.1% |
| Inventory | $9.62M | $14.43M | $10.21M | $14.16M | — | -33.3% |
| Total current assets | $123.84M | $90.37M | $117.02M | $230.43M | — | +37.0% |
| Property, plant & equipment | $14.82M | $17.12M | $23.50M | $33.01M | — | -13.4% |
| Goodwill & intangibles | $27.61M | $31.86M | $20.29M | $27.20M | — | -13.4% |
| Total assets | $185.55M | $144.22M | $167.53M | $294.30M | — | +28.7% |
| Total current liabilities | $49.74M | $71.40M | $84.91M | $127.72M | — | -30.3% |
| Current debt | — | $625.00K | $3.00M | $10.18M | $5.32M | — |
| Long-term debt | $59.50M | $57.96M | $60.86M | $93.14M | — | +2.7% |
| Total debt | $74.30M | $75.96M | $84.66M | $127.34M | — | -2.2% |
| Total liabilities | $123.36M | $145.87M | $165.94M | $244.28M | — | -15.4% |
| Retained earnings | -$734.05M | -$740.87M | -$694.87M | -$634.23M | — | +0.9% |
| Shareholder equity | $49.87M | $22.74M | $22.54M | $41.72M | — | +119.3% |
| Working capital | $74.10M | $18.97M | $32.11M | $102.72M | — | +290.6% |
| Net tangible assets | $22.27M | -$9.13M | $2.26M | $14.52M | — | +344.0% |
| Shares issued | 31.36M | 27.91M | 15.09M | 7.37M | — | +12.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$32.91M | -$120.86M | -$154.15M | -$213.91M | — | +72.8% |
| Depreciation & amortisation | $4.66M | $4.46M | $6.00M | $9.35M | — | +4.4% |
| Stock-based compensation | $28.74M | $32.62M | $17.03M | $22.99M | — | -11.9% |
| Change in working capital | -$25.10M | -$8.13M | -$12.52M | -$715.00K | — | -208.8% |
| Operating cash flow | -$65.78M | -$80.19M | -$128.22M | -$179.40M | — | +18.0% |
| Capital expenditure | — | -$15.00M | -$8.10M | -$3.06M | -$16.35M | — |
| Investing cash flow | $10.12M | -$15.00M | -$2.10M | -$22.93M | — | +167.5% |
| Share buybacks | -$265.00K | $0 | -$400.00K | -$1.20M | — | — |
| Dividends paid | -$664.00K | -$4.71M | -$8.77M | -$8.78M | — | +85.9% |
| Financing cash flow | $77.44M | $70.64M | $32.74M | $75.32M | — | +9.6% |
| Free cash flow | -$65.78M | -$95.19M | -$136.32M | -$182.46M | — | +30.9% |
| End cash position | $80.60M | $58.81M | $83.36M | $180.95M | — | +37.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $18.72M | $16.04M | $16.08M | $17.63M | $16.41M | +16.7% |
| Operating revenue | $17.84M | $15.92M | $16.07M | $17.02M | $15.01M | +12.0% |
| Cost of revenue | $6.14M | $6.22M | $5.44M | $5.75M | $4.94M | -1.2% |
| Gross profit | $12.57M | $9.82M | $10.64M | $11.88M | $11.47M | +28.1% |
| Research & development | $805.00K | $540.00K | -$367.00K | $208.00K | $8.13M | +49.1% |
| Selling, general & admin | $20.81M | $15.89M | $14.73M | $17.41M | $38.76M | +30.9% |
| Total operating expense | $22.58M | $17.56M | $15.43M | $18.69M | $47.95M | +28.6% |
| Operating income | -$10.01M | -$7.74M | -$4.79M | -$6.81M | -$36.47M | -29.3% |
| Net interest income | $105.00K | -$2.80M | -$1.40M | -$2.01M | -$1.90M | +103.8% |
| Pre-tax income | $922.00K | $142.29M | -$6.21M | $8.85M | -$11.65M | -99.4% |
| Tax provision | $320.00K | $5.13M | -$816.00K | $26.00K | $0 | -93.8% |
| Net income | -$468.00K | $110.37M | -$3.94M | $5.85M | $15.49M | -100.4% |
| Net income to common | -$2.48M | $108.36M | -$6.20M | $3.67M | $13.36M | -102.3% |
| EBIT | $2.17M | $144.06M | -$4.50M | $11.27M | -$9.58M | -98.5% |
| EBITDA | $3.24M | $145.28M | -$3.35M | $12.43M | -$8.42M | -97.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $196.58M | $255.84M | $79.38M | $86.22M | $74.39M | — | -23.2% |
| Cash & short-term investments | $196.58M | $255.84M | $79.38M | $86.22M | $74.39M | — | -23.2% |
| Accounts receivable | $36.25M | $24.99M | $29.78M | $17.98M | $15.64M | — | +45.0% |
| Inventory | $8.16M | $9.29M | $9.62M | $11.82M | $12.85M | — | -12.2% |
| Total current assets | $245.51M | $295.48M | $123.84M | $118.50M | $110.40M | — | -16.9% |
| Property, plant & equipment | $13.77M | $14.25M | $14.82M | $14.93M | $15.52M | — | -3.4% |
| Goodwill & intangibles | $25.51M | $26.48M | $27.61M | $28.67M | $29.73M | — | -3.7% |
| Total assets | $316.71M | $356.87M | $185.55M | $181.41M | $159.90M | — | -11.3% |
| Total current liabilities | $62.02M | $103.39M | $49.74M | $54.07M | $57.52M | — | -40.0% |
| Current debt | $5.00M | $2.50M | — | $5.63M | $3.75M | $1.88M | +100.0% |
| Long-term debt | $34.60M | $36.88M | $59.50M | $47.77M | $50.03M | — | -6.2% |
| Total debt | $53.32M | $53.63M | $74.30M | $68.29M | $69.22M | — | -0.6% |
| Total liabilities | $110.63M | $154.50M | $123.36M | $116.22M | $122.51M | — | -28.4% |
| Retained earnings | -$624.15M | -$623.68M | -$734.05M | -$730.12M | -$735.97M | — | -0.1% |
| Shareholder equity | $164.14M | $162.21M | $49.87M | $55.86M | $43.92M | — | +1.2% |
| Working capital | $183.49M | $192.09M | $74.10M | $64.44M | $52.88M | — | -4.5% |
| Net tangible assets | $138.63M | $135.73M | $22.27M | $27.19M | $14.19M | — | +2.1% |
| Shares issued | 33.31M | 33.19M | 31.36M | 31.01M | 29.75M | — | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $602.00K | $137.16M | -$5.40M | $8.83M | -$11.65M | -99.6% |
| Depreciation & amortisation | $1.06M | $1.22M | $1.16M | $1.16M | $1.16M | -12.8% |
| Stock-based compensation | $2.88M | $1.76M | $2.46M | $3.20M | $16.79M | +63.9% |
| Change in working capital | -$53.64M | $55.79M | -$10.80M | -$4.53M | -$7.48M | -196.1% |
| Operating cash flow | -$59.28M | $203.85M | -$12.54M | -$6.11M | -$27.56M | -129.1% |
| Investing cash flow | -$79.00K | $0 | $0 | $2.87M | $6.09M | — |
| Share buybacks | $0 | -$14.34M | $0 | $0 | -$115.00K | +100.0% |
| Dividends paid | -$141.00K | $0 | -$166.00K | -$166.00K | -$166.00K | — |
| Financing cash flow | $91.00K | -$27.39M | $5.71M | $15.07M | $4.52M | +100.3% |
| Free cash flow | -$59.36M | $203.85M | -$12.54M | -$6.11M | -$27.56M | -129.1% |
| End cash position | $197.80M | $257.06M | $80.60M | $87.44M | $75.61M | -23.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $21.57M | +22.4% |
| Next quarter | — | — | $22.46M | +39.7% |
| Current year | — | — | $78.79M | +24.6% |
| Next year | — | — | $113.25M | +43.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.00%
Held by institutions0.00%
Institutions holding0
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
17.08
+5.56% from price
SMA 20
17.49
+3.11% from price
SMA 50
18.26
-1.27% from price
SMA 100
18.75
-3.86% from price
SMA 200
15.70
+14.83% from price
EMA 12
17.46
+3.27% from price
EMA 26
17.67
+2.03% from price
EMA 50
17.97
+0.33% from price
RSI (14)
54.0
Neutral
MACD (12,26,9)
-0.21
Hist 0.18
ATR (14)
0.68
3.77% of price
Realised vol 30D
32.2%
Annualised
Bollinger upper
19.07
20, 2σ
Bollinger lower
15.90
20, 2σ
50 / 200 cross
Golden
18.26 vs 15.70
Trend bias
Above 200
+14.83%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.40
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
32.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-23.8%
Peak to trough
Max drawdown 5Y
-81.1%
Peak to trough
ATR 14
0.68
3.77% of price
Beta (reported)
1.25
5Y monthly, from filing
Short interest
Shares short
0
Prior 710
Change vs prior
-100.0%
Shorts covering
% of float
—
—
% of shares out
—
Against total outstanding
Days to cover
0.0
Liquid
Float
21.44M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield12.09%
Payout ratio—
Ex-dividend dateJun 14, 2024
Next pay dateJun 30, 2024
Last split—
Split date—
Headlines
Journey Medical Corporation to Participate in September 2026 Investor Conferences
GlobeNewswire · 29d ago
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 29d ago
Fortress Biotech, Inc. Q2 2026 Earnings Call Summary
Moby · 54d ago
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript
Motley Fool · 55d ago
Fortress Biotech: Q2 Earnings Snapshot
Associated Press · 55d ago
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
GlobeNewswire · 55d ago
Fortress Biotech Q2 Earnings Call Highlights
MarketBeat · 56d ago
Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
GlobeNewswire · 56d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.